U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C15H10Cl2N4O6
Molecular Weight 413.169
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OPICAPONE

SMILES

CC1=C(C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl

InChI

InChIKey=ASOADIZOVZTJSR-UHFFFAOYSA-N
InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3

HIDE SMILES / InChI

Molecular Formula C15H10Cl2N4O6
Molecular Weight 413.169
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Opicapone (Ongentys®), a potent, oral, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as the adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson's disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Opicapone is a hydrophilic 1,2,4-oxadiazole analog with a pyridine N-oxide at position 3, with these modifications enhancing its potency and extending its duration of action, whilst avoiding cell toxicity. In preclinical animal studies, Opicapone-induced inhibition of peripheral (but not central) COMT activity was associated with a prolonged increase in systemic and central exposure to L-Dopa, with a corresponding reduction in 3-OMD exposure. Following single or multiple doses of Opicapone (5–1200 mg) in healthy adult volunteers or patients with PD, Opicapone inhibited COMT activity in ex vivo erythrocyte assays in a reversible dose-dependent manner, with the duration of Opicapone-induced COMT inhibition independent of dose. Adjunctive Opicapone was generally well tolerated during more than a year of treatment in BIPARK I and BIPARK II (double-blind plus extension phases). The recommended dosage is 50 mg once daily, which should be taken at bedtime at least 1 h before or after L-Dopa combinations.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ongentys

Approved Use

Unknown

Launch Date

2016
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
95 ng/mL
5 mg 1 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
301 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
58 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
343 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
424.5 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
756.2 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
238 ng × h/mL
5 mg 1 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1441 ng × h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
124 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1432 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1321 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2244 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.1 h
5 mg 1 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.97 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
0.92 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
0.1%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OPICAPONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day single, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: single
Dose: 1200 mg, 1 times / day
Sources:
healthy, 18-45 years
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Disc. AE: Nausea, Constipation...
AEs leading to
discontinuation/dose reduction:
Nausea (2%)
Constipation (1.4%)
Hallucination (1%)
Dizziness (1%)
Dyskinesia (1%)
Sources:
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Disc. AE: Dyskinesia...
Other AEs: Dyskinesia, Dizziness...
AEs leading to
discontinuation/dose reduction:
Dyskinesia (3%)
Other AEs:
Dyskinesia (20%)
Dizziness (3%)
Constipation (6%)
Dry mouth (3%)
Hallucination (3%)
Insomnia (3%)
Blood creatine increased (5%)
Weight decreased (4%)
Hypotension orthostatic (5%)
Hypertension (3%)
Sources:
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Other AEs: Nausea...
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
DLT: Depression, Abnormal behaviour...
Disc. AE: Creatine kinase increased, Creatine kinase increased...
Dose limiting toxicities:
Depression (grade 1, 0.4%)
Abnormal behaviour (grade 3, 0.4%)
AEs leading to
discontinuation/dose reduction:
Creatine kinase increased
Creatine kinase increased
Pulmonary embolism (grade 3, 0.4%)
Cholecystitis acute (grade 3, 0.4%)
Delirium febrile (grade 2, 0.4%)
Head injury (grade 3, 0.4%)
Atrioventricular block complete (grade 1, 0.4%)
Hallucination, auditory (grade 3, 0.4%)
Sources:
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Disc. AE: Osteoarthritis, Superficial spreading melanoma...
AEs leading to
discontinuation/dose reduction:
Osteoarthritis (grade 1, 0.4%)
Superficial spreading melanoma (grade 1, 0.4%)
Malignant melanoma (grade 3, 0.4%)
Jealous delusion (grade 3, 0.4%)
Sources:
5 mg 1 times / day steady, oral
Studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Disc. AE: Hepatic enzyme increased...
AEs leading to
discontinuation/dose reduction:
Hepatic enzyme increased (grade 2, 0.2%)
Sources:
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Hallucinations, Visual hallucinations...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1.7%)
Visual hallucinations (0.3%)
Sources:
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (2%)
Sources:
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Hallucinations...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1.7%)
Sources:
5 mg 1 times / day steady, oral
Studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Hallucinations...
AEs leading to
discontinuation/dose reduction:
Hallucinations (0.8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 1%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Dyskinesia 1%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Hallucination 1%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Constipation 1.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Nausea 2%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 67.7 years
Health Status: unhealthy
Age Group: 67.7 years
Sex: M+F
Sources:
Dyskinesia 20%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Dizziness 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Dry mouth 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Hallucination 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Hypertension 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Insomnia 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Dyskinesia 3%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Weight decreased 4%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Blood creatine increased 5%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Hypotension orthostatic 5%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Constipation 6%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Nausea 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Creatine kinase increased Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Creatine kinase increased Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Depression grade 1, 0.4%
DLT
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Atrioventricular block complete grade 1, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Delirium febrile grade 2, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Abnormal behaviour grade 3, 0.4%
DLT
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Cholecystitis acute grade 3, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Hallucination, auditory grade 3, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Head injury grade 3, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Pulmonary embolism grade 3, 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Osteoarthritis grade 1, 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Superficial spreading melanoma grade 1, 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Jealous delusion grade 3, 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Malignant melanoma grade 3, 0.4%
Disc. AE
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Hepatic enzyme increased grade 2, 0.2%
Disc. AE
5 mg 1 times / day steady, oral
Studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adults
Health Status: unhealthy
Age Group: adults
Sex: M+F
Sources:
Visual hallucinations 0.3%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Hallucinations 1.7%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Nausea and vomiting 2%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Hallucinations 1.7%
Disc. AE
25 mg 1 times / day steady, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
Hallucinations 0.8%
Disc. AE
5 mg 1 times / day steady, oral
Studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
no
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
no
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes [IC50 1.089 uM]
no (co-administration study)
Comment: 0.45 μg/mL. studies demonstrated no clinically relevant interaction with repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 13.0
yes [IC50 10.55 uM]
yes [IC50 13.16 uM]
no (co-administration study)
Comment: 6.7 μg/mL, studies demonstrated no clinically relevant interaction with repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 27.0
yes [IC50 14.75 uM]
yes [IC50 2.178 uM]
no (co-administration study)
Comment: 0.9 μg/mL, studies demonstrated no clinically relevant interaction with repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 27.0
yes [IC50 22.22 uM]
yes [IC50 25.92 uM]
yes [IC50 3.388 uM]
yes [IC50 40.65 uM]
no (co-administration study)
Comment: 20.7 μg/mL, clinical studies demonstrated no clinically relevant interaction with warfarin (CYP2C9 substrate) or repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 27.0
yes [IC50 43.57 uM]
no (co-administration study)
Comment: 18 μg/mL, clinical studies demonstrated no clinically relevant interaction with warfarin (CYP2C9 substrate) or repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 27.0
yes [IC50 5 uM]
yes [IC50 5.5 uM]
no (co-administration study)
Comment: 2.80 ug/ml, studies demonstrated no clinically relevant interaction with repaglinide (CYP2C8 and OATP1B1 substrate)
Page: 13.0
yes [IC50 72.61 uM]
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
yes
unlikely
Comment: CYP-mediated clinically relevant drug interactions perpetrated by OPC or its metabolite BIA 9-1103 are considered unlikely when taking into consideration the relevant free (unbound) Cmax following 50 mg dosing for OPC and its major metabolite.
Page: 13.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: Following administration of OPC 1 hour after 600 mg quinidine, median Tmax for OPC was approximately 1.5 hours later compared to when OPC was administered alone. OPC exposure (Cmax and AUC parameters) were approximately 30% to 37% lower when administered after quinidine compared to administration alone.
Page: 13.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.
2010 Apr 22
A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
2014 Jun 26
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
2016 Feb
Patents

Sample Use Guides

The recommended dosage is 50 mg once daily, which should be taken at bedtime at least 1 h before or after L-Dopa combinations
Route of Administration: Oral
COMT inhibition by Opicapone was evaluated in rat liver homogenates by measuring the formation of metanephrine (O-methylated adrenaline) Opicapone was under tight-binding conditions at a 10-fold lower concentration of 3 μM.The reactionmixture (total volume of 1 mL) contained homogenate (2 mg/mL), NCE (3 μM for nitrocatechols or 30 μM for non-nitrocatechols), 100 μM MgCl2 , 1 mM EGTA, 100 μM pargyline, and S-adenosyl-L-methionine (500 μM) in phosphate buffer (5 mM, pH 7.8). After a 20 min preincubation period at 37 C, the reaction was initiated with adrenaline (1000 μM when testing nitrocatechols or 25 μM when testing nonnitrocatechols) and proceeded for 5 min at 37 C. Reactions were terminated with the addition of 1/10 volume of 2 N perchloric acid. Samples were centrifuged (16000g for 3 min at 4 C) and filtered through 0.22 μm pore size Spin-X 200 filters. Metanephrine was then quantified by HPLC with electrochemical detection as previously detailed
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:12:37 GMT 2025
Edited
by admin
on Mon Mar 31 20:12:37 GMT 2025
Record UNII
Y5929UIJ5N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OPICAPONE
INN   WHO-DD  
INN  
Official Name English
1,2-BENZENEDIOL, 5-(3-(2,5-DICHLORO-4,6-DIMETHYL-1-OXIDO-3-PYRIDINYL)-1,2,4-OXADIAZOL-5-YL)-3-NITRO-
Preferred Name English
5-(3-(2,5-DICHLORO-4,6-DIMETHYL-1-OXY-PYRIDIN-3-YL)-(1,2,4)OXADIAZOL-5-YL)-3-NITROBENZENE-1,2-DIOL
Systematic Name English
BIA 9-1067
Code English
OPICAPONE [JAN]
Common Name English
OPICAPONE [MI]
Common Name English
OPICAPONE [USAN]
Common Name English
BIA-9-1067
Code English
ONGENTYS
Brand Name English
opicapone [INN]
Common Name English
2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE N-OXIDE
Systematic Name English
BIA-91067
Code English
Opicapone [WHO-DD]
Common Name English
OPICAPONE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC N04BX04
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
Code System Code Type Description
PUBCHEM
135565903
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
INN
9268
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
FDA UNII
Y5929UIJ5N
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
MESH
C549349
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
USAN
FG-121
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
SMS_ID
100000156709
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
RXCUI
2362167
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
WIKIPEDIA
Opicapone
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
MERCK INDEX
m11976
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
CAS
923287-50-7
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
DAILYMED
Y5929UIJ5N
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID601026417
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
EVMPD
SUB130629
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
DRUG CENTRAL
5143
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
DRUG BANK
DB11632
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
NCI_THESAURUS
C170258
Created by admin on Mon Mar 31 20:12:37 GMT 2025 , Edited by admin on Mon Mar 31 20:12:37 GMT 2025
PRIMARY
Related Record Type Details
BINDER->LIGAND
independent of concentration
BINDING
EXCRETED UNCHANGED
After administration of a single dose of radiolabeled opicapone 100 mg (2 times the recommended dosage) to healthy subjects
FECAL
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
After administration of a single dose of radiolabeled opicapone 100 mg (2 times the recommended dosage) to healthy subjects
URINE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TARGET -> INHIBITOR
Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MINOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE DOSE ADMINISTRATION

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC FED CONDITION

MODERATE FAT/MODERATE CALORIE MEAL